VELA Investment Management LLC Purchases 12,983 Shares of Supernus Pharmaceuticals, Inc. $SUPN

VELA Investment Management LLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 25.2% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 64,594 shares of the specialty pharmaceutical company’s stock after purchasing an additional 12,983 shares during the quarter. VELA Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $3,004,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the company. Public Employees Retirement System of Ohio acquired a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $25,000. Rockefeller Capital Management L.P. boosted its position in shares of Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after purchasing an additional 660 shares in the last quarter. EverSource Wealth Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $51,000. Hantz Financial Services Inc. grew its stake in Supernus Pharmaceuticals by 73.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after purchasing an additional 458 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in Supernus Pharmaceuticals in the second quarter worth approximately $55,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on SUPN shares. Zacks Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Stock Performance

Shares of NASDAQ:SUPN opened at $43.53 on Monday. The business’s 50 day simple moving average is $46.69 and its two-hundred day simple moving average is $48.39. The firm has a market cap of $2.53 billion, a P/E ratio of -22.67, a PEG ratio of 0.80 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 52-week low of $42.45 and a 52-week high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The firm had revenue of $219.06 million during the quarter, compared to analyst estimates of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company’s revenue was up 32.4% on a year-over-year basis. During the same period last year, the business posted $0.40 EPS. On average, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.